Metastatic Pancreatic Cancer Clinical Trial
Official title:
Phase Ib/II Clinical Study of Adebrelimab in Combination With Decitabine, Albumin-bound Paclitaxel, and Gemcitabine for the First-line Treatment of Metastatic Pancreatic Cancer
Pancreatic cancer is a kind of digestive system tumor with extremely high malignancy and poor prognosis. Although the trend of benefit from immunotherapy in combination with chemotherapy is currently reflected in several exploratory studies, the overall efficacy is still relatively limited. Dysregulation of epigenetic mechanisms, which is common in cancer, leads to down-regulation of genes involved in tumor antigen processing or presentation, resulting in immune evasion and thus affecting the efficacy of immunotherapy. Epigenetic inhibitors may enhance the efficacy of immunotherapy by enhancing antigenicity and presentation of tumor-associated antigens, reprogramming the tumor microenvironment to counteract immunosuppression, and reversing cytotoxic T-cell depletion. Thus, decitabine-promoted immunotherapeutic sensitization is a potential therapeutic avenue for mPDAC patients that warrants further exploration in clinical trials. Taking into account the characteristics of pancreatic cancer immunophenotype, exploring combination therapy regimens that enhance anti-tumor immune response and improve the efficacy of immunotherapy has become an urgent clinical problem. This study is a prospective, single-arm, single-center, phase IB/II clinical study exploring the efficacy and safety of adebrelimab in combination with decitabine, albumin-bound paclitaxel, and gemcitabine in the first-line treatment of metastatic pancreatic cancer. The primary study endpoints are DLT, RP2D and ORR. Secondary study endpoints are OS, PFS, DCR, DoR and safety.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04753879 -
Multi-agent Low Dose Chemotherapy GAX-CI Followed by Olaparib and Pembro in Metastatic Pancreatic Ductal Cancer.
|
Phase 2 | |
| Completed |
NCT01417000 -
Safety and Efficacy of Combination Listeria/GVAX Immunotherapy in Pancreatic Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT02975141 -
Afatinib and Gemcitabine/Nab-paclitaxel in Metastatic Pancreatic Cancer
|
Phase 1 | |
| Active, not recruiting |
NCT00761345 -
Study of Low-Dose Fractionated Radiotherapy in Patients With Locally Advanced Metastatic Pancreatic Cancer
|
Phase 1 | |
| Completed |
NCT00919282 -
Gemcitabine (GFF) in Patients With Pancreatic Cancer
|
Phase 2 | |
| Completed |
NCT01088815 -
Hedgehog Inhibitors for Metastatic Adenocarcinoma of the Pancreas
|
Phase 2 | |
| Completed |
NCT04133155 -
Retrospective Analysis of 2nd-line Nab-Paclitaxel + Gemcitabine After 1st-line FOLFIRINOX in Pancreatic Cancer
|
||
| Withdrawn |
NCT05251038 -
Study of Sotorasib Combined With Chemotherapy for Second Line Treatment of Pancreas Cancer
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04612530 -
PANFIRE-3 Trial: Assessing Safety and Efficacy of Irreversible Electroporation (IRE) + Nivolumab + CpG for Metastatic Pancreatic Cancer
|
Phase 1 | |
| Completed |
NCT03602885 -
EL CENTRO: Engaging Latinos in the Center of Cancer Treatment Options
|
N/A | |
| Recruiting |
NCT05442749 -
Niraparib as First Line Therapy With Metastatic Homologous Repair-deficient Pancreatic Cancer
|
Phase 2 | |
| Recruiting |
NCT04222413 -
Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT03721744 -
A Study of GB201 in Combination With Weekly Paclitaxel and Low-dose Gemcitabine in Patients With Pancreatic Cancer
|
Phase 2/Phase 3 | |
| Completed |
NCT03261947 -
A Study to Evaluate the Safety, Tolerability, and Activity of TAK-931 in Participants With Metastatic Pancreatic Cancer, Metastatic Colorectal Cancer, and Other Advanced Solid Tumors
|
Phase 2 | |
| Withdrawn |
NCT06017323 -
Proglumide With Gemcitabine and Nab-Paclitaxel in PatientsWith Metastatic Pancreatic Ductal Adenocarcinoma
|
Phase 1 | |
| Terminated |
NCT01946646 -
Phase I Study of TS-1 With Concurrent Radiotherapy to Treat Pancreatic Cancer
|
Phase 1 | |
| Completed |
NCT01523457 -
Study of Modified FOLFIRINOX in Advanced Pancreatic Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT00986661 -
A Study to Assess PV-10 Chemoablation of Cancer of the Liver
|
Phase 1 | |
| Terminated |
NCT00726037 -
A Pilot Study, Evaluating the Efficacy of Regulatory T-cell Suppression by Ontak in Metastatic Pancreatic Cancer
|
Phase 2 | |
| Completed |
NCT00744640 -
Gemcitabine, Oxaliplatin and Capecitabine for Advanced Pancreatic Carcinoma
|
Phase 1/Phase 2 |